Abrocitinib Attenuates Microglia-Mediated Neuroinflammation after Traumatic Brain Injury via Inhibiting the JAK1/STAT1/NF-κB Pathway

Abrocitinib Attenuates Microglia-Mediated Neuroinflammation after Traumatic Brain Injury via Inhibiting the JAK1/STAT1/NF-κB Pathway

Background and Purpose: Neuroinflammation has been shown to play a critical role in secondary craniocerebral injury, leading to poor outcomes for TBI patients. Abrocitinib, a Janus kinase1 (JAK1) selective inhibitor approved to treat atopic dermatitis (AD) by the Food and Drug Administration (FDA),...

Full description

Bibliographic Details
Main Authors: Tuo Li, Lei Li, Ruilong Peng, Hongying Hao, Hejun Zhang, Yalong Gao, Cong Wang, Fanjian Li, Xilei Liu, Fanglian Chen, Shu Zhang, Jianning Zhang
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Cells
Subjects:
TBI
abrocitinib
neuroinflammation
JAK1/STAT1/NF-κB
Online Access:https://www.mdpi.com/2073-4409/11/22/3588

Internet

https://www.mdpi.com/2073-4409/11/22/3588

Similar Items